Kornimate/medical-research-clean huggingface dataset:
assessment of the outcome of endodontic treatment using cone beam computed tomography.

Conditions: Periapical Periodontitis

Summary: the aim of the study is to assess the correlation between pre-obturation bacterial detection using fluorescence amplification and outcome of endodontic treatments. thus, enabling a suitable detection threshold to predict the likelihood of treatment failure. this has the potential to be used a bench side tool in general dental practice to act as a surrogate endpoint for clinicians performing root canal treatment.

pre-obturation root canal samples were taken using paper points from patients undergoing primary root treatments. the samples were analyzed using a fluorescent spectrometer and a molecular fluorescent vital dye (calcein am). pre-operative and 1-year post-operative periapical radiographs and cone beam computed tomography (cbct) scans were assessed by two calibrated expert examiners to evaluate the outcome of the root canal treatments. the use of a chairside bacterial stain can allow the clinician to predict the outcome of treatment with confidence. sampling the root canal space with endodontic paper points followed by ex-situ fluorescent staining and analysis provides a patient-friendly, simple to use and rapid way of predicting root canal treatment outcome.

Eligibility criteria:
inclusion criteria: * patients with at least one tooth diagnosed with the endodontic disease. * teeth that were tender to percussion and palpation. * teeth that had a sinus tract and/ swelling. * both primary treatment teeth and teeth which had already been root treated were considered. exclusion criteria: * patients were excluded if they were pregnant. * immunosuppressed patients. * non-restorable teeth. * teeth with a periodontal probing depth greater than 3mm. * teeth with apical radiolucencies with the longest dimension above 1.2cm.
effectiveness of paritaprevir/ritonavir - ombitasvir, ± dasabuvir, ± ribavirin in patients with chronic hepatitis c - an observational study in belgium

Conditions: Chronic Hepatitis C, Genotype 1 or 4

Summary: the interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (abbvie regimen) ± ribavirin (rbv) for the treatment of chronic hepatitis c (chc) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well-controlled conditions. this observational study was the first effectiveness research examining the abbvie regimen ± rbv, used according to local label, under real world conditions in belgium in a clinical practice patient population.

this was a prospective, multi-center observational study in participants receiving the interferon-free abbvie regimen ± rbv in belgium. the prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the participant the opportunity to participate in this study. adults chronically infected with hepatitis c virus (hcv), receiving the interferon-free abbvie regimen, were offered the opportunity to participate in this study during a routine clinical visit at the participating sites.follow-up visits, treatment, procedures, and diagnostic methods followed physicians' routine clinical practice. data were collected at the following time windows: baseline, early on-treatment visit, mid-treatment visit (for participants with a treatment duration of 24 weeks), end of treatment (eot), early post-treatment, and 12 and 24 weeks after the end of treatment (representing sustained virologic response 12 weeks after the end of treatment \[svr12\] and sustained virologic response 24 weeks after the end of treatment \[svr24\]).

Eligibility criteria:
inclusion criteria: * treatment-naïve or -experienced adult male or female participants with confirmed chronic hepatitis c (chc), genotype 1 or 4, receiving combination therapy with the interferon-free abbvie regimen ± ribavirin (rbv) according to standard of care and in line with the current local label * if rbv was co-administered with the abbvie regimen, it had to be prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy) * participants had to voluntarily sign and date an informed consent form prior to inclusion into the study * participants must not have participated or intended to participate in a concurrent interventional therapeutic trial exclusion criteria: • none

Keywords: effectiveness influence of adherence patient reported outcomes ombitasvir/paritaprevir/ritonavir ± dasabuvir chronic hepatitis c genotype 1 chronic hepatitis c genotype 4
hepasphere interventional therapy using digital subtraction angiography（dsa） for liver cancer

Conditions: Liver Cancer

Summary: the purpose of this study is to evaluate the safety and efficacy of hepasphere interventional therapy using digital subtraction angiography（dsa） for liver cancer.

by enrolling patients with liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of hepasphere interventional therapy using digital subtraction angiography（dsa） for liver cancer.

Eligibility criteria:
inclusion criteria: 1. age:18-80 2. karnofsky performance status \>60 3. diagnosis of pancreatic cancer based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. will receive interventional therapy 6. life expectancy: greater than 3 months 7. patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except pancreatic cancer 2. history of coagulation disorders or anemia

Keywords: liver cancer hepasphere
resilience evaluation of caregivers during the sars-cov2 epidemic period : prospective cohort.

Conditions: Psychological

Summary: the outbreak linked to sars-cov-2 infection was declared a public health emergency of international concern on 30 january 2020. in all of the emergency departments, a major reorganization was necessary, notably with the creation of a specific channel for covid-19 suspect patients. thus, all caregivers involved must adapt day by day to new places of exercise, new protocols,...the major influx of patients, the precautions to be taken, the specifics of the pathology and its management have profoundly changed daily practice. this exogenous hospital tension impacts all caregivers and more particularly their resilience capacities. resilience is defined as an ability to recover from or adjust easily to misfortune or change. the resi-cov study aims to assess the level of resilience of caregivers of different specialties and trades in the context of covid-19.

caregivers will be invited to complete a self-administered questionnaire online via a personalized electronic message. caregivers will be free to participate. signed consent will not be requested, but the return of the questionnaire will be considered consent. the questionnaire will be administered using google form® software. caregivers will have 2 weeks to respond. a reminder will be made at 7 days. the questionnaire will be anonymized upon receipt by the investigator.

Eligibility criteria:
inclusion criteria: * caregivers (physicians, nurses) * working in the emergency department, anaesthesiology, infectious department, intensive care unit. * voluntary to answer the questionnaire exclusion criteria: - working in another department

Keywords: caregivers covid-19 resilience questionnaire cd-risc 25
upper extremity rehabilitation using robot and botulinum toxin

Conditions: Stroke; Spasticity

Summary: concomitant use of botulinum toxin and robot would make better results regarding upper extremity function compared to robot, botulinum toxin, or no intervention.


Eligibility criteria:
inclusion criteria: * hemiplegic patients secondary to first cerebrovascular accidents * shoulder or elbow flexor spasticity above or modified ashworth scale 1+ * cognitively intact enough to understand and follow the instructions from the investigator exclusion criteria: * history of surgery of affected upper limb * fracture of affected upper limb * recent history of botulinum toxin injection within 6 months

Keywords: stroke spasticity
microbiota and the lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the subject is to study the lung microbiota and the one of upper airways (uas) (much less studied than the intestinal microbiota) in 40 patients having lung cancer. 20 patients undergo only surgical treatment, while other half receives also chemotherapy. the idea is to explore changes in microbiota of the lung, upper uas and intestine, and potentially find associations between them. these results will serve us as a base for the future study, focused on manipulation of the microbiota by prebiotics, probiotics or symbiotics and its effect on anti-cancer treatment tolerance and effectiveness.

lung cancer patients will be divided in two groups, a first one with patients undergoing both chemotherapy and surgery (pct-chir), and the second one with patients only undergoing surgery (pchir). following inclusion, they will be given a 7-days alimentary survey, along with blood and saliva sampling (after buccodental examination and dental panoramic). the pct-chir group will repeat the same procedure after the chemotherapy and before the surgery. day before the surgery, patients are asked to bring their faecal samples (in special box provided in advance) and the filled survey. during the operation the piece of lung tissue as well as the tumour (if the size enables it) will be sampled for further analysis. lavage will be performed on the lung immediately after its resection. saliva, faecal sample, lung and tumour tissue, and lavage will be used for bacterial dna extraction, followed by qpcr and sequencing analysis. lavage and blood samples will be analysed by flow cytometry and elisa, to establish the immunological profile (interleukines, cell surface markers).

Eligibility criteria:
inclusion criteria: * non small cell lung carcinoma patient suitable for surgery, or chemotherapy followed by surgery * bmi \<29.9 kg/m² * not taking antibiotics, corticosteroids and/or immunosuppressants at least during two months before inclusion * not taking prebiotics, probiotics or symbiotics at least during two months before inclusion * signing the written consent before enrollment in the study * affiliation to the national health insurance (or system alike) according to the law from 9th august 2004 exclusion criteria: * cognitive difficulties * refusal of participation or inability to give a clear consent * digestive or pulmonary infection of a long duration during the two months preceding the study (with antibiotic treatment) * inflammatory digestive pathology * concurrent treatment with experimental medication, participation in another clinical therapeutic study within 30 days * presence of colostomy, total or partial gastrectomy * previous esophageal surgery * previous orl (otho-rhino-laryngo) cancer treated by radiotherapy or surgery * patient enable to follow the requirements of the study * patient deprived of his rights by administrative or judicial decision

Keywords: lung cancer intestinal microbiota lung microbiota surgery chemotherapy
mesohep ii: intraperitoneal low molecular weight heparin in peritoneal dialysis

Conditions: Inflammation; Nutrition; Peritoneal Dialysis

Summary: patients with end stage renal disease (esrd) who use peritoneal dialyses with physioneal(r) (baxter a/s, denmark) were allocated to inject either placebo or tinzaparin daily into the morning dialysis bag. active medication, as well as placebo, was added for three months separated by a one month washout period. at the beginning and end of each treatment period peritoneal equilibrations tests (pe-tests), kt/v, blood and dialysate samples were analyzed. we, the researchers at ribe county hospital, set out to examine inflammation (local and systemic), nutrition and ultrafiltration.


Eligibility criteria:
inclusion criteria: * end stage renal disease * peritoneal dialysis without complication for minimum of three months * 18 years or above * informed consent exclusion criteria: * known coagulatory defects including anticoagulation therapy * known bleeding tendency * peritonitis within two months prior to inclusion * pregnancy * breast feeding * active infection * non-informed consent * allergy to heparin or prior heparin induced thrombocytopenia
berberine, chlorogenic acid and tocotrienols in menopause-associated dyslipidemia

Conditions: Dyslipidemia

Summary: menopause is usually associated with an increase in body weight, a change in body composition and fat distribution and a large number of cardio-metabolic changes, such as hypertension, reduction of insulin-sensitivity and dyslipidaemia. the first-line strategy for these complications is the modification of dietary habits and lifestyle in terms of physical activity. besides, there is also a growing interest in complementary therapies (i.e. nutraceuticals) that can be used alone or in combination to achieve more consistent results. in this context, preliminary evidence supports the potential role of some compounds of vegetal origin such as berberine, chlorogenic acid and tocotrienols. however, in support of their use, the evidence from good quality trials is limited.


Eligibility criteria:
inclusion criteria: * ldl cholesterol \>100 mg/dl * written informed consent available exclusion criteria: * use of any drug affecting blood lipids * hormone replacement therapy * adherence to a weigh loss diet in the previous 6 months * cancer diagnosis * known thyroid, liver, renal or muscle diseases * any medical or surgical condition which could lead to an inconstant adhesion to the protocol
tms-eeg for cortical excitability

Conditions: Acquired Brain Injury; Stroke; Traumatic Brain Injury; Healthy

Summary: this research study is being done to look at the safety and diagnostic benefit of conducting an tms(transcranial magnetic stimulation)-eeg measured before and after a brief experimental stimulation session using investigational devices repetitive tms or transcranial direct current stimulation (tdcs).


Eligibility criteria:
inclusion criteria - stroke: - acquired brain injury such as ischemic or hemorrhagic stroke or traumatic brain injury. inclusion criteria - healthy controls: - no known active neurological disorder. exclusion criteria - stroke: * pregnancy * contraindication to mri or tms including metallic implanted objects. * medical instability or inability to cooperate during the study as assessed by the treating physician to participate in the study. * severe aphasia. * history of epilepsy. * history of active depression or treatment resistant depression. * history of schizophrenia. exclusion criteria - healthy controls: * pregnancy * contraindication to mri or tms including metallic implanted objects. * history of acquired brain injury.
dental support device during breastfeeding as a mean for pain control

Conditions: Breastfeeding

Summary: leboride is a dental support device that was developed for reducing pain during active labor. it is made of an inert material, placed in the woman's mouth and does not disturb breathing, talking, or any other activity expected during labor. it is a single-use device, each user receives a new one. this study hypothesis is that the leboride use can reduce pain during breastfeeding, by that improve women's breastfeeding experience, and increase breastfeeding rates.

dental support device is effective in increasing isometric force in different muscle contraction \[1-7\]. in 2009 an avant-garde study \[8\] found in a small cohort that dental support device during labor, can shorten the second stage and reduce obstetrical interventions such as operative delivery and cesarean section. in this stage the woman has to contract muscles in order to push the fetus through the birth canal. leboride is a dental support device that was developed for reducing pain during active labor. it is made of an inert material, placed in the woman's mouth and does not disturb breathing, talking, or any other activity expected during labor. it is a single-use device, each user receives a new one. this study hypothesis is that the leboride use can reduce pain during breastfeeding, by that improve women's breastfeeding experience, and increase breastfeeding rates.

Eligibility criteria:
inclusion criteria: maternal age 18-45 years. normal vital signs. exclusion criteria: contraindications for breastfeeding. significant systemic disease that cause pain or require chronic pain relief.
sleep during weight loss and weight loss maintenance

Conditions: Sleep; Weight Loss

Summary: the purpose of the study is to examine the changes of sleep during weight loss and weight loss management. the research staff will also obtain data on sleep disturbances, insomnia symptoms, risk of sleep apnea, circadian preferences, weight loss self-efficacy, emotional eating, executive functioning, loneliness and social isolation, and patients' beliefs about how sleep might impact their weight control or vice versa.

this study is an observational study using a longitudinal data collection design with non-invasive measures. fifty participants who are about to begin the healthy lifestyle program (hlp) at the weight and wellness clinic (wwc) and another 50 participants who are about to complete hlp will be recruited to the study. after informed consent is obtained, the patient will be asked to complete several questionnaires about sleep and wellbeing. their height and weight will also be measured by the research staff. the patient will then be given a wrist-worn accelerometer to wear for 16 weeks to measure their sleep and physical activity. they will be asked to complete the same set of questions at approximately the 8th and 16th week at a research visit. data on existing diagnosis of sleep disorders will be extracted from the patients' electronic medical records.

Eligibility criteria:
inclusion criteria: * adult overweight or obese patients who are enrolled in or who completed the healthy lifestyle program at weight and wellness center.exclusion criteria:

Keywords: weight loss sleep
real-world use of adjuvant nivolumab in patients with upper gastrointestinal cancer in canada

Conditions: Upper Gastrointestinal Cancer

Summary: the purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.


Eligibility criteria:
inclusion criteria: * enrolled in bristol-myers squibb gastroesophageal opdivo in resected patients with residual pathological disease patient support program (george psp) in canada * patients who have consented to the use of their de-identified data generated from information collected in the course of the george psp exclusion criteria: * aged \<18 years * did not receive concurrent chemoradiotherapy prior to surgery * positive margins following resection * no residual disease following complete resection
a study to evaluate response of overactive bladder symptom score (oabss) to treatment

Conditions: Overactive Bladder

Summary: this study is to evaluate change of overactive bladder symptom scores (oabss) between, before and after solifenacin treatment to oab subjects.


Eligibility criteria:
inclusion criteria: * symptoms oab for 3 months or longer * at least 3 urgency episode in last 3 days * symptoms of oab as verified by the screening 3-day bladder diary, defined by: * number of micturition ≥8 times/day * number of urgency episodes in 3 days ≥3 exclusion criteria: * significant stress incontinence or mixed stress/urge incontinence * subject with indwelling catheters or practicing intermittent self-catheterization * symptomatic urinary tract infection, chronic inflammation * diabetic neuropathy * subjects who are prohibited from taking solifenacin as contraindications * drug or non-drug treatment for oab was started, quitted or changed in 4 weeks * participation in any clinical trial in 30 days except for part-1 of resort

Keywords: oabss ipss ppbc 3-day micturition diary solifenacin
bnt162b2 messenger ribonucleic acid (mrna) covid-19 vaccine in cancer patients on active treatment

Conditions: Neoplasms; Cancer, Treatment-Related

Summary: in this italian observational study the antibody titer reactogenicity to pfizer severe acute respiratory syndrome (sars) - coronavirus (cov-2) rna vaccine in cancer patients under active antitumor treatment will be evaluated at 21 and 42 days and after 6 months. furthermore patients safety will be monitored. factors affecting immunogenicity (or lack of), including cancer treatment, will be the primary aim of the study.

this is an observational non-interventional study in cancer patients. the study will evaluate the safety, tolerability and immunogenicity of pfizer sars-cov-2 rna vaccine against coronavirus disease-19 (covid-19) which will be delivered in the deltoid muscle in 2-dose (separated by 21 days). blood will be collected in two 5 milliliters (ml) vacuettes for serum immunoglobulin g (igg) and cytokine assessment, at baseline and after 21 days, immediately before the first and the second dose, respectively, then after 42 days from the first dose and finally after 6 months from the baseline. a panel of 22 cytokines (biorad) will be measured at baseline and after 21 and 42 days in four groups consisting of: no responders (s1/s2 igg\ 15 au/ml after the second dose), fast responders (s1/s2 igg\>15 au/ml after the first 21 days) and immunized patients (s1/s2 igg\>15 au/ml at baseline). at baseline, at 42 days and 6 months questionnaires for psychological testing will be dispensed for completion to patients. after 42 days from the first dose, 15 ml of heparinized peripheral blood from both non-responders (s1/s2 igg\<25 au/ml) and responders will be used for isolation of different cluster of differentiation 4 (cd4+) and cd8+ t cell subpopulations and analysis of their capability to undergo activation/proliferation in response to specific sars- cov-2 derived peptides.

Eligibility criteria:
inclusion criteria: * age ≥18 years * on treatment for cancer during the last 6 months or being treated \>6 months ago but being ultravulnerable * about to receive "pfizer-biontech covid-19" vaccine * lymphocyte count≥0.5x10\^9/l exclusion criteria: * subjects who are not eligible for "pfizer-biontech covid-19" vaccine administration * inability and/or unwillingness to sign written informed consent

Keywords: neoplasms covid-19 pfizer sars- cov-2 rna vaccine